Financial News Feed

Stronger Sell Today ACOR ranks #4875 as SELL CANDIDATE. Weaker Sell
Today ACOR ranks #4875 as SELL CANDIDATE.

ACOR stock Acorda Therapeutics

ACOR stock
Acorda Therapeutics

Acorda Therapeutics (ACOR) has ended the week in the red, yielding negative results for the shares at they ticked -4.63%. In taking a look at recent performance, we can see that shares have moved 2.33...

Read more

Investors sentiment decreased to 0.99 in Q3 2018. Its down 0.46, from 1.45 in 2018Q2. It dived, as 24 investors sold Acorda Therapeutics, Inc. shares while 52...

Read more

Active investors may be taking a second look at shares of Acorda Therapeutics, Inc. (NasdaqGS:ACOR). Checking in on some levels, the six month price index is currently at 0.55780. The six month price ...

Read more

In reviewing some key ratios and quant data for SEACOR Holdings Inc. (NYSE:CKH), we note that the mother of all ratios (Return on Equity) stands at 0.192100 for the firm. ROE reveals what percentage o...

Read more

Investors sentiment decreased to 0.99 in 2018 Q3. Its down 0.46, from 1.45 in 2018Q2. It dived, as 24 investors sold Acorda Therapeutics, Inc. shares while 52 reduced holdings. 31 funds opened positio...

Read more

Investors sentiment decreased to 0.99 in 2018 Q3. Its down 0.46, from 1.45 in 2018Q2. It worsened, as 24 investors sold Acorda Therapeutics, Inc. shares while 52 reduced holdings. 31 funds opened posi...

Read more

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 1,700 shares of the business’s stock in a transaction on Tuesday, January 15th. The shares were sold at an a...

Read more

During Q3 2018 the big money sentiment decreased to 0.99. That's change of 0.46, from 2018Q2's 1.45. 24 investors sold all, 52 reduced holdings as Acorda...

Read more

Bowling Portfolio Management LLC boosted its holdings in Acorda Therapeutics Inc (NASDAQ:ACOR) by 521.1% during the 4th quarter, Holdings Channel reports. The firm owned 84,495 shares of the biopharma...

Read more

Acorda Therapeutics (ACOR)’s indicators and moving averages are pointing to a potential reversal at the Chikou line has ducked under the Tenkan, indicating that a reversal of price might be nearing....

Read more

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The stock was s...

Read more

Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 1,700 shares of the firm’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold...

Read more

Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Other EventsItem 8.01Other Events On January 17, 2019, Acorda Therapeutics, Inc. issued a press release announcing that The Lancet Neurology publish...

Read more

HC Wainwright set a $33.00 price objective on Acorda Therapeutics (NASDAQ:ACOR) in a report released on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. ACO...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank